Clinical Trials Logo

Graves' Orbitopathy clinical trials

View clinical trials related to Graves' Orbitopathy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05276063 Active, not recruiting - Eye Diseases Clinical Trials

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

LIDS
Start date: July 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).